

Supplementary Table 1. Treatment utilisation for the non-TI and TI cohorts

	Non-TI cohort N=1025			TI cohort N=1832		
	n of users (%)	mean (SD) PPPM	median [IQR] PPPM	n of users (%)	mean (SD)	median [IQR]
MF treatment						
JAK inhibitors						
Ruxolitinib (Jakavi)	540 (52.7)	0.72 (0.36)	0.81 [0.43–1.04]	956 (52.2)	0.57 (0.36)	0.55 [0.26–0.93]
Fedratinib (Inrebic)	Freq <10	0.24 (0.42)	0.05 [0.02–0.26]	Freq <10	0.05 (0.04)	0.04 [0.03–0.06]
Peginterferon α -2a (or other interferons)	29 (2.8)	0.51 (0.4)	0.47 [0.2–0.81]	174 (9.5)	0.44 (0.55)	0.32 [0.1–0.68]
Immunomodulatory agents	27 (2.6)	0.29 (0.26)	0.2 [0.07–0.47]	17 (0.9)	0.39 (0.38)	0.24 [0.07–0.6]
Glucocorticoids	458 (44.7)	0.35 (0.41)	0.16 [0.06–0.61]	965 (52.7)	0.18 (0.27)	0.07 [0.03–0.16]
Allogenic stem cell transplant	41 (4)	0.07 (0.11)	0.04 [0.02–0.07]	79 (4.3)	0.04 (0.06)	0.02 [0.01–0.04]
Splenectomy	Freq <10	0.06 (0.02)	0.06 [0.05–0.07]	13 (0.7)	0.05 (0.09)	0.02 [0.01–0.03]
Splenic radiation	32 (3.1)	0.54 (0.82)	0.3 [0.08–0.6]	49 (2.7)	0.27 (0.3)	0.15 [0.04–0.41]
Hydroxyurea	183 (17.9)	0.49 (0.37)	0.41 [0.21–0.7]	683 (37.3)	0.5 (0.32)	0.47 [0.22–0.78]
Treatments for anaemia[†]						
Blood transfusions	763 (74.4)	1.14 (1.16)	0.82 [0.25–1.63]	644 (35.2)	0.26 (0.44)	0.1 [0.04–0.32]
Anti-anaemic preparations	395 (38.5)	0.37 (0.37)	0.23 [0.09–0.62]	742 (40.5)	0.24 (0.27)	0.13 [0.05–0.34]
Iron preparations	114 (11.1)	0.3 (0.45)	0.11 [0.04–0.39]	362 (19.8)	0.15 (0.21)	0.06 [0.03–0.18]
Vitamin B12 and folic acid	334 (32.6)	0.36 (0.33)	0.25 [0.08–0.61]	558 (30.5)	0.25 (0.26)	0.13 [0.05–0.35]
Erythropoiesis-stimulating agents	516 (50.3)	0.75 (0.41)	0.84 [0.39–1.05]	600 (32.8)	0.5 (0.39)	0.42 [0.18–0.79]

Epoietin α	275 (26.8)	0.64 (0.45)	0.59 [0.23–1.01]	319 (17.4)	0.4 (0.36)	0.31 [0.09–0.61]
Darbepoetin α	310 (30.2)	0.67 (0.41)	0.69 [0.3–1.01]	357 (19.5)	0.47 (0.39)	0.4 [0.15–0.73]
Methoxy polyethylene glycolepoietin β	Freq <10	0.6 (0.24)	0.46 [0.4–0.86]	Freq <10	0.13 (0.12)	0.08 [0.06–0.13]
Androgens	Freq <10	0.17 (0.25)	0.07 [0.03–0.31]	Freq <10	0.23 (0.29)	0.14 [0.01–0.45]
Danazol	47 (4.6)	0.35 (0.28)	0.29 [0.13–0.59]	30 (1.6)	0.27 (0.27)	0.17 [0.06–0.41]
Other therapies						
Anagrelide	28 (2.7)	0.41 (0.28)	0.34 [0.17–0.57]	193 (10.5)	0.25 (0.23)	0.19 [0.06–0.39]
Antifibrinolytics	64 (6.2)	0.14 (0.23)	0.06 [0.03–0.1]	106 (5.8)	0.07 (0.11)	0.03 [0.02–0.06]
Opioids	495 (48.3)	0.36 (0.65)	0.16 [0.05–0.44]	1002 (54.7)	0.23 (0.62)	0.07 [0.03–0.2]
Folic acid analogues	Freq <10	0.08 (0.08)	0.06 [0.02–0.17]	Freq <10 (0.5)	0.2 (0.19)	0.14 [0.08–0.22]
Colony-stimulating factors	68 (6.6)	0.25 (0.35)	0.11 [0.04–0.25]	60 (3.3)	0.19 (0.26)	0.06 [0.04–0.22]
Iron chelating agents (including: Deferoxamine, Deferiprone, Deferasirox)	262 (25.6)	0.58 (0.44)	0.52 [0.22–0.89]	63 (3.4)	0.23 (0.23)	0.14 [0.07–0.3]
Anti-infectives for systemic use	807 (78.7)	0.55 (0.52)	0.36 [0.15–0.86]	1516 (82.8)	0.31 (0.34)	0.16 [0.07–0.44]
J01 (antibacterials for systemic use)	753 (73.5)	0.39 (0.39)	0.24 [0.12–0.54]	1446 (78.9)	0.2 (0.24)	0.11 [0.06–0.23]
J02 (antimycotics for systemic use)	230 (22.4)	0.25 (0.39)	0.1 [0.04–0.32]	329 (18)	0.1 (0.13)	0.05 [0.02–0.11]
J04 (antimycobacterials)	14 (1.4)	0.21 (0.2)	0.12 [0.08–0.19]	16 (0.9)	0.16 (0.14)	0.12 [0.04–0.3]
J05 (antivirals for systemic use)	359 (35)	0.5 (0.35)	0.51 [0.14–0.81]	585 (31.9)	0.35 (0.34)	0.24 [0.05–0.6]

PPPM describes number of prescriptions per user during follow-up. †Treatments for anaemia related to MF.

IQR, interquartile range; JAK, Janus kinase; MF, myelofibrosis; PPPM, per person per month; SD, standard deviation; TI, transfusion-independent.